3 not yet recruiting, 2 active not recruiting, 2 completed, 1 recruiting. 5 Phase 2, 4 Phase 1, 3 Early Phase 1.
Follow B-Cell Acute Lymphoblastic Leukemia, Adult: new trials by email Literature Review of B-Cell Acute Lymphoblastic Leukemia, Adult trials Research Report on B-Cell Acute Lymphoblastic Leukemia, Adult
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2026-09-01 | 2026-08-11 |
| Allogeneic UCB-derived CAR-T for B-ALL allogeneic umbilical cord blood-derived CAR-T - B-Cell Acute Lymphoblastic Leukemia, Adult | Early Phase 1 | Not yet recruiting | The General Hospital of Western Theater Command | 50 | 2025-12-01 | 2025-12-01 |
| Autologous Bedside CD19 CAR T-cell Therapy for B-ALL CD19 CAR T cells - B-Cell Acute Lymphoblastic Leukemia, Adult | Early Phase 1 | Not yet recruiting | The General Hospital of Western Theater Command | 50 | 2025-12-01 | 2025-12-11 |
| Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia blinatumomab combined with venetoclax as maintenance therapy - B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 2 | Active not recruiting | Zhejiang University | 24 | 2025-06-01 | 2025-09-30 |
| Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia QH10304-BAL-01, Fludarabine, Cyclophosphamide - B-Cell Acute Lymphoblastic Leukemia, Adult | Early Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | 18 | 2024-12-01 | 2024-11-20 |
| Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL CAR-T cells targeting CD19 and CD22 - B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 2 | Completed | Zhejiang University | 28 | 2021-03-05 | 2024-10-17 |
| Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL CAR-T cells targeting CD19 and CD22 - B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Unknown | Zhejiang University | 50 | 2021-01-31 | 2021-02-05 |
| CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies Fludarabine, Cyclophosphamide, CD19-CD34 CAR transduced T cells - B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory | Phase 1 | Active not recruiting | Loyola University | 24 | 2019-12-31 | 2022-08-15 |
| Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts blinatumomab, pembrolizumab - B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Completed | University of California, San Diego | 16 | 2017-08-04 | 2025-11-10 |
Burkitt Lymphoma (9) · Leukemia (1) · Lymphoma (1) · Recurrence (1)
DNA Virus Infections (9) · Epstein-Barr Virus Infections (9) · Hemic and Lymphatic Diseases (9) · Herpesviridae Infections (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Infections (9) · Lymphatic Diseases (9) · Lymphoma, B-Cell (9) · Lymphoma, Non-Hodgkin (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Tumor Virus Infections (9) · Virus Diseases (9)
Cyclophosphamide (2) · blinatumomab (2) · fludarabine (2) · Maintenance (1) · pembrolizumab (1) · venetoclax (1)
Zhejiang University (3) · The General Hospital of Western Theater Command (2) · Loyola University (1) · Memorial Sloan Kettering Cancer Center (1) · The First Affiliated Hospital of Soochow University (1) · University of California, San Diego (1)
China (6) · United States (3)
Hai Yi, M.D. & Ph.D. (2) · Hongyan Tong (1) · Jae Park, MD (1) · James K Mangan, M.D., P.h.D. (1) · Nasheed Hossain, MD (1) · Xiaowen Tang, Ph.D (1)